ArticleJournal of endocrinological investigation2026
Cancer incidence in endogenous hypercortisolism.
Article in Journal of endocrinological investigation, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
purposeEvidence regarding incident malignancy in endogenous hypercortisolism remains limited. We evaluated cancer risk across the spectrum of cortisol excess and identified predictors of malignancy.
methodsThis retrospective single-center cohort study included 347 patients with endogenous hypercortisolism (138 overt Cushing's syndrome and 209 mild autonomous cortisol secretion). Patients with active malignancy at baseline were excluded. Incident cancers diagnosed after hypercortisolism diagnosis were identified through hospital records. Observed malignancies were compared with age- and sex-specific national cancer incidence rates to calculate standardized incidence ratios (SIRs). Cox regression analyses were performed to assess predictors of incident cancer.
resultsA total of 42 incident malignancies (12.1%) occurred during a median follow-up of 87 months (IQR, 35-129). Overall cancer incidence was significantly higher than expected (42 observed vs. 12.27 expected; SIR 3.42, 95% CI 2.47-4.63). Risk was increased in overt Cushing's syndrome (SIR 5.12, 95% CI 3.07-7.97), adrenal Cushing's syndrome (SIR 4.94, 95% CI 2.26-9.37), Cushing's disease (SIR 5.27, 95% CI 2.53-9.69), and mild autonomous cortisol secretion (SIR 2.68, 95% CI 1.70-4.02). Thyroid cancer was the most frequent malignancy (31.0%). Excess risk persisted after excluding thyroid cancers (overall SIR 2.52, 95% CI 1.69-3.62). In univariable analyses, diabetes mellitus, severe obesity, and HbA1c ≥ 64 mmol/mol were associated with incident malignancy in overt Cushing's syndrome, while bilateral adrenal tumors were associated with incident malignancy in adrenal Cushing's syndrome.
conclusionsEndogenous hypercortisolism is associated with increased incident cancer risk, particularly in overt Cushing's syndrome. Long-term oncologic vigilance may be warranted.
Indexed as
Identifiers
42593715What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.